Affiliation:
1. 1 „Dr. Ion Cantacuzino” Clinical Hospital , Bucharest , Romania
2. 2 „Carol Davila” University of Medicine and Pharmacy , Bucharest , Romania
3. 3 Colţea Clinical Hospital , Bucharest , Romania
Abstract
Abstract
Background. Myeloproliferative disorders define a vast and heteregenous group of neoplastic entities, characterized by malignant proliferation of blood cells. These may affect multiple tissues, some of these malignancies involving organs in which there is lymphoid tissue.
Case report. A 81-year-old female patient was admitted to the Department of Internal Medicine with moderate-to-intense spontaneous pain in the left hypochondrial and in the left abdominal flank, associated with generalized fatigue and loss of appetite. According to the personal medical history, the patient is known with type II diabetes mellitus, being under treatment with oral antidiabetics (metformin 1000 mg), and arterial hypertension under treatment with candesartan. Upon admission, the physical examination revealed cutaneous and mucosal pallor and marked physical weakness. Abdominal palpation revealed pain in the left hypochondrial and in the left abdominal flank, associated with firm and massive splenomegaly, descending towards the umbilicus. Abdominal ultrasound confirmed massive splenomegaly, associated with moderate hepatomegaly. Blood analysis revealed several modifications, indicative of hypochromic normocytic anemia, associated with lymphocytosis, thrombocytopenia and neutropenia. C-reactive protein (CRP) serum levels were in normal range upon admission. All of these modifications suggested a possible leukemogenous or lymphoid malignancy, which resulted in the patient's transfer towards the Department of Hematology, for further investigations.
Conclusions. Massive splenomegaly, associated with anemia and thrombocytopenia in elderly patients, should always indicate a leukemogenous or lymphoid malignancy and a thorough differential diagnosis and collaboration between internists and hematologists is required.
Reference18 articles.
1. Zinzani P.L. The many faces of marginal zone lymphoma. ASH Educ Progr B. 2012;2012(1):426–432.
2. Lenglet J., Traullé C., Mounier N., Benet C., Munoz-Bongrand N., Amorin S. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. Leuk Lymphoma. 2013;55:1854–1860.
3. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H. In: World Health Organization classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al., editors. International Agency for Research on Cancer (IARC); Lyon: 2008. International Agency for Research on Cancer (IARC). 422 p.
4. Behdad A., Bailey N.G. Diagnosis of splenic B-cell lymphomas in the bone marrow: a review of histopathologic, immunophenotypic, and genetic findings. Arch Pathol Lab Med. 2014;138(10): 1295–1301.
5. Traverse-Glehen A., Baseggio L., Salles G., Felman P., Berger F. Splenic marginal zone B-cell lymphoma: a distinct clinicopathological and molecular entity. Recent advances in ontogeny and classification. Curr Opin Oncol. 2011;23(5):441–448.